Clinical Trial

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Study acronym: PHOENYCS FLY
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Protocol Amendment History 3 changes
notable Trial sites expanded: 233 -> 236 locations 2026-08-08
notable Trial sites expanded: 219 -> 225 locations 2026-05-02
notable Trial sites expanded: 214 -> 219 locations 2026-04-04
Trial Details
NCT Number NCT06617325
Lead Sponsor UCB Biopharma SRL
Conditions Systemic Lupus Erythematosus
Enrollment 450 participants
Start Date 2024-11-21
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-07